Slide 1: Noninvasive Accurate Lung Cancer Detection: Company Overview Presentation
_ 2 Noninvasive Accurate Lun¢ cer Detection ®) At in ity Seema TECHNOLOGIES Nasdaq; Company Overview Presentation Autumn 2026
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation and statements by management or other persons acting by or on behalf of bioAffinity Technologies made in connection with this presentation constitute “forward-looking statements” within the meaning of the sa
Slide 3: Lung Cancer Is A Global Problem and Large Market
Lung Cancer Is A Global Problem and Large Market Most common cancer and leading cause of cancer-related deaths 2.48 Million 1.8 Million New cases worldwide annually: Deaths annually’ An estimated 19.3 million Americans should have annual lung rs) Major Screening Need in the United States cancer scre
Slide 4: Early Detection of Lung Cancer Saves Lives
Early Detection of Lung Cancer Saves Lives Improving survival rates through timely intervention and accurate diagnosis Current Survival Rates cn) In 2025, less than 30% of patients survived 5 years? The Power of Early Detection Late-Stage Diagnosis x] Most patients are diagnosed with late-stage canc
Slide 5: CyPath Lung Platform
CyPath® Lung Platform Detecting Lung Cancer with Noninvasive Technology 92% 87% 99% 88% Sensitivity ' Specificity ' NPV" Accuracy! 5oa a = Proprietary Al Analysis Patient-Friendly & Physician-Focused Growing Platform Technology Al-driven algorithm analyzes complex flow ; At-home collection (no needl
Slide 6: Physician-Focused, Patient-Friendly, Reimbursed by Insurance
Physician-Focused, Patient-Friendly, Reimbursed by Insurance & @ wm @ Clinic @ Home @ Laboratory @ Clinic Physician orders Patient videos, instructions, Al-driven automated Physician receives CyPath®Lung test to and personal coach assist with analysis of flow cytometry results within 3 days ship to
Slide 7: CyPath Lung in Action: Patient Case Studies
CyPath Lung in Action: Patient Case Studies* ; Demonstrating Detection at Curative Stage 1A & Averting Risky Procedures bioAffinity TECHNOLOGIES (s-) LIKELY MALIGNANCY cin} LIKELY MALIGNANCY Co} UNLIKELY MALIGNANCY "Gloria" "Paula" "James" Challenge: PET scan and serum markers Challenge: Bronchoscop
Slide 8: CyPath Lung in Action: Patient Case Studies
CyPath Lung in Action: Patient Case Studies* Case Studies Demonstrate Cancer Detection In Surveillance Period; Earlier Detection of Malignant Ground Glass Nodule bioAffinity TECHNOLOGIES e LIKELY MALIGNANCY “Joan" Challenge: Surveillance in high-risk survivors is challenging. CyPath® Result: Returne
Slide 9: Market Opportunity
Market Opportunity The U.S. Market for CyPath® Lung is poised for significant growth © 2030 Market Opportunity Indeterminate Pulmonary Nodules 29MM AA 47MM $470 MM 2025 +62% 2030 The total number of indeterminate pulmonary nodules G@ | At 10% Market Share nodules (IPNs) detected by lung cancer scree
Slide 10: Market Opportunity
Market Opportunity CyPath® Lung Use for Surveillance of Lung Cancer Recurrence 20 2030 Market Opportunity $7.76 MM Lung Cancer Survivors 680,450 <A” 871,580 2025 428% 2035 & | At 10% Market Share The total number of people living with lung cancer is projected to increase by 28% from 680,450 survivor
Slide 11: Revenue & Key Business Milestones Achieved in 2025
Revenue & Key Business Milestones Achieved in 2025 Jan '25 A Solid Foundation for Growth 100% 6 9: oO Increase / jaaiieatl Published multiple case Entered major VA Phased field expansion Expanded indications CyPath® Lung YoY case studies and medical centers with in Northeast and for surveillance and
Slide 12: Accelerated Growth and Expansion in 2026
Accelerated Growth and Expansion in 2026 2026 Building on a Solid Foundation for Growth 100%+ 6 iM) Weare) Q2 sales increased over Longitudinal clinical Continued Strategic R&D expanding 2026 Forecast 216% YoY with a 120+% trial opens with DOW field expansion in technology platform CyPath® Lung YoY
Slide 13: How the Test Works
How the Test Works Flow Cytometry Interrogates Lung Microenvironment Sputum samples are processed into a single-cell suspension and labelled before data acquisition with antibodies, reagents, labeling agents and TCPP. Proprietary Al-Driven Platform Analysis Automated analysis identifies cell populat
Slide 14: Longitudinal Clinical Trial Launched in 2026
Longitudinal Clinical Trial Launched in 2026 Sen 9. “s 2, 2,000 20+ Q1 2026 Patient Enrollment Collection Sites Enrollment Started Designed to assess CyPath® Lung performance for risk stratification, clinical decision-making, detection, and survivor surveillance. o) Collection sites include more tha
Slide 15: Significant Healthcare Savings
Significant Healthcare Savings Economic Impact Analysis i 2024 study! authored by pulmonologists practicing at Audie L. Murphy Memorial VA Hospital and Brooke Army Medical Center evaluated CyPath’ Lung's potential economic impact if added to the standard of care. a Medicare Patient Commercial Insura
Slide 16: Building on a Successful Diagnostic Platform
Bu ding on a Successful Diagnostic Platform Next in Pipeline: Companion Diagnostics for Asthma and COPD Quantifying Lung Inflammation for Improved Therapy Precision Diagnostics Match patients to effective treatments and monitor their effectiveness over time, ensuring optimal therapeutic outcomes. In
Slide 17: Management
Management Innovative, Experienced, Dedicated | Executive Leadership ° a »b (4 a a Matia Zannes, 3D Xavier Reveles, MS Michael Edwards, MBA William Bauta, PhD Gordon Downie, MD, PhD Founder, CEO & President Chief operating officer Chief Financial Officer Chief Science Officer Chief Medical officer 3
Slide 18: Board of Directors
Board of Directors Decades of Successful Leadership from Start-Ups to Global Corporations Steve Girgenti Executive Chairman Founded leading global healthcare marketing firm Healthworld with 32 offices worldwide. Recognized as NASDAQ's 1999 “Entrepreneur of the Year.” Jamie Platt, PhD Director 20+ ye
Slide 19: Maria Zannes
Maria Zannes President & CEO &% mz@bioaffinitytech.com & 505-400-9747 oot ffo, bioAffinity TECHNOLOGIES bloaffinity Technologies (Nasdaq: BIAF) |